Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | F3 | P13726 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3374470 | 0.90 | POLB (0.47) | POLBKMT2AHSD17B10GAAHPGD | |
| SCHEMBL3377862 | 0.89 | POLB (0.45) | POLBKMT2AHSD17B10GAAHPGD | |
| SCHEMBL3373245 | 0.86 | KDM4E (0.39) | KMT2AHSD17B10HPGDKDM4ENPSR1 | |
| SCHEMBL3376132 | 0.86 | POLB (0.43) | POLBKMT2AHSD17B10GAAHPGD | |
| SCHEMBL3378393 | 0.85 | CA12 (0.43) | KMT2AKDM4ESMN1; SMN2NPSR1MEN1 | |
| SCHEMBL3377852 | 0.84 | MEN1 (0.48) | KMT2AHSD17B10HPGDKDM4ESMN1; SMN2 | |
| SCHEMBL3373263 | 0.83 | TSHR (0.50) | KMT2AHPGDKDM4ESMN1; SMN2NPSR1 | |
| SCHEMBL3377879 | 0.81 | MEN1 (0.39) | POLBKMT2AHPGDKDM4ESMN1; SMN2 | |
| SCHEMBL3376465 | 0.80 | ALDH1A1 (0.40) | POLBKMT2AHPGDKDM4ESMN1; SMN2 | |
| SCHEMBL3377959 | 0.80 | MEN1 (0.39) | KMT2AHSD17B10HPGDKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1517886-B1 | NOVEL PHTHALAMIDE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2010-11-10 | — | — | EP | disclosed |
| US-7132455-B2 | Phthalamide derivatives | BAYER CROPSCIENCE AG (DE) | 2006-11-07 | — | — | US | disclosed |
| US-20060035967-A1 | Novel phthalamide derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-02-16 | — | — | US | disclosed |
| EP-1517886-A1 | NOVEL PHTHALAMIDE DERIVATIVES | Bayer CropScience AG (DE) | 2005-03-30 | — | — | EP | disclosed |
| WO-2004000796-A1 | NOVEL PHTHALAMIDE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035967-A1 | Novel phthalamide derivatives | HDAC1, HDAC2, CRY1 | POLB 4159/4885KMT2A 102/4885HSD17B10 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.